Celecoxib

For research use only.

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

33 publications

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 420 In stock
USD 70 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Celecoxib has been cited by 33 publications

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MoPmSpVv[3Srb36gRZN{[Xl? NX;U[m9GOC5zLUOwJO69VQ>? NIO2e4g1QCCq NXTUR2dHcW6mdXPld{BKS0GPLUGg[ZhxemW|c3nvckBwdiCkb4ToJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wx? MmSxNlY2OTNzN{K=
H460 NXnQNnF4TnWwY4Tpc44hSXO|YYm= MkfaNE4yNTNyIN88US=> MlfzOFghcA>? M3nVc4lv\HWlZYOgTWNCVS1zIHX4dJJme3Orb36gc44h[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVt NXfLdVd5OjZ3MUOxO|I>
HKESC-2 NH;XdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonZNlDDqM7:TR?= NUG5OWpDPDkEoHlCpC=> NWXre5FDe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi NFu2UFQzPjR5NE[5Ny=>
CaES-17 NWrVU2dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVWyNOKh|ryP NH\tSoI1QMLiaNMg NG\DRlB{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW|IH;mJI95[WyrcHzheIlvyqB? NH32eFkzPjR5NE[5Ny=>
HKESC-2 MVjBdI9xfG:|aYOgRZN{[Xl? M1PmRVIxyqEQvF2= NXS4WVZmPDkEoHlCpC=> M1HSUpJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> MUGyOlQ4PDZ7Mx?=
CaES-17 MmHURZBweHSxc3nzJGF{e2G7 MkKxNlDDqM7:TR?= M{XhWFQ5yqCqwrC= M4XCXpJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> NGXx[|kzPjR5NE[5Ny=>
A549 NEKwNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;FW3lWPS1zNkCg{txO MWO0POKhcMLi MlvVSG1UVw>? NIqzRW5KSzVyPUG2N{41KM7:TR?= MWSyOlQ3PDZ2Mx?=
HCC827 MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3iwOFUuOTZyIN88US=> NGC3RYQ1QMLiaNMg NILzNY1FVVOR NWDYRoRPUUN3ME22PU4zKM7:TR?= NWr2PGROOjZ2NkS2OFM>
A549 M4r5NGFxd3C2b4Ppd{BCe3OjeR?= NF;6eYE5OCEEtV2= NXPUcXoxPDkEoHlCpC=> MXzEUXNQ NH7PZ4NqdmS3Y3XzJIFxd3C2b4Ppdy=> MlWzNlY1PjR4NEO=
HCC827 NFXBSmJCeG:ydH;zbZMhSXO|YYm= NX\YZldbQDBiwsXN NU\ZVlVHPDkEoHlCpC=> NVTSfVZtTE2VTx?= NHjDPJZqdmS3Y3XzJIFxd3C2b4Ppdy=> NWfjTlN1OjZ2NkS2OFM>
SGC-7901/DDP NGS4e49HfW6ldHnvckBCe3OjeR?= MVKxNOKhyrWP MUGyOEBp NWPo[GlwcW6qaXLpeJMh[3mlbH;vfJlo\W6jc3WtNkBidmRiUD3ncJlkd3C{b4TlbY4h\XiycnXzd4lwdg>? MUKyOlQxPzZ3Mx?=
SGC-7901  NGXM[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmyOOKhcMLi NG\Qd3hKSzVyPUGxOU4xQCEQvF2= NF3ZS5QzPjRyN{[1Ny=>
SGC-7901/DDP M1rUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXRPIkzPMLiaNMg MoDPTWM2OD1|NT60OUDPxE1? MnG2NlY1ODd4NUO=
SGC-7901/DDP NHnFbJBCeG:ydH;zbZMhSXO|YYm= M3HWe|ExyqEEtV2= MWmyOEBp NIi4c5hqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIIfpeIgh[2m|cHzheIlv M3zXOVI3PDB5NkWz
SGC-7901/DDP MXjGeY5kfGmxbjDBd5NigQ>? NITY[pIyOMLiwsXN MW[yOEBp MWjpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDQMYdtgWOxcILveIVqdiC2aILveYdpKGKub3PrbY5oKEWSMjygZY5lKGmwYXP0bZZifGmwZzDQT2Eh[W6mIFPSSWLDqA>? M{fuVFI3PDB5NkWz
SGC-7901/DDP MYDGeY5kfGmxbjDBd5NigQ>? MnL4NVDDqML3TR?= MVmyOEBp NVrpPVBG[2G3c3XzJIEhdWG{a3XkJIRm[3KnYYPlJIlvKHSqZTDs[ZZmdCCxZjDCZ4wuOiCycn;0[Ylv NFfUOVQzPjRyN{[1Ny=>
H357 NVvlcVJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjVNHM4NjVxMUCg{txO MVK0PEBp MmLHSG1UVw>? M1LHTYlvcGmkaYTzJINmdGxiZ4Lve5RpyqClb33ibY5m\CC5aYToJHNi[nW2b3PsZZg> NYD5WJYzOjZyMEm4O|Q>
TAF MY\GeY5kfGmxbjDBd5NigQ>? MlzPNVDDqML3TR?= MY[3JIQ> MUTh[oZm[3S|IGTBSpMh[WSqZYPpeoUheHKxcHXyeIlmew>? MYWyOVk5PzF{Nx?=
TAF MUXGeY5kfGmxbjDBd5NigQ>? MnyzNVDDqML3TR?= NFXH[pc{OC1zMkCgcYlv Mn\kdI9wemy7IHHm[oVkfHNiZFHreEBxcG:|cHjvdplt[XSrb36gZ49ve2WzdXXueEB1dyCHR1[gd4lodmGuaX7n NU\Wfm5WOjV7OEexNlc>
TAF MVrGeY5kfGmxbjDBd5NigQ>? NWLyRW5rOTEEoNM1US=> NGfKfJU1QCCq M2PhVIlv[3KnYYPld{BGT0[UIH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NGT2OVEzPTl6N{GyOy=>
PANC-1 MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C4Z|IxNzZyL{GwNEDPxE1? M2rudFI1NzR6L{eyJIg> M2rMfIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MW[yOVk4OzB4Mh?=
PANC-1 M2njemZ2dmO2aX;uJGF{e2G7 NGe0VFMzOC94MD:xNFAh|ryP MUiyOEBp MXLheJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA> NV;oepFQOjV7N{OwOlI>
HeLa  MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrQXHQzOMLizszNxsA> M3;vWFI1yqCq MUflcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? NH3MbIszPTd5MESyNy=>
SACC-83 M2Xmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TvRVIxyqEQvF5CpC=> NULpdJl6OjUEoHi= MWXlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? NHLjXlMzPTd5MESyNy=>
HeLa  NF3ub4FCeG:ydH;zbZMhSXO|YYm= NGfOT|YzOMLizszNxsA> NH3xdYYzPMLiaB?= NVraUpFH\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>? NXf0XZp6OjV5N{C0NlM>
SACC-83 NHHIdINCeG:ydH;zbZMhSXO|YYm= NVX3coxCOjEEoN88UeKh NYjMdoxVOjUEoHi= MlvY[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=> MXSyOVc4ODR{Mx?=
HeLa  M4[5XmZ2dmO2aX;uJGF{e2G7 NX3zdJR5OjBxNECvPFAh|ryP MkHNNlTDqGh? M{flfpVxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV MXmyOVc4ODR{Mx?=
SACC-83 M2fJOGZ2dmO2aX;uJGF{e2G7 M1rDO|IxNzRyL{iwJO69VQ>? Mne3NlTDqGh? NVHvN|J3fXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R? Ml;UNlU4PzB2MkO=
HLCZ01 M17NOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGw5qCUPjEEoNM1US=> NIm4VJM1QCCq NX;5NXpyTE2VTx?= M17vS4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NUjD[GF5OjV5MkS4PVk>
HLCZ01 NF7KSpJHfW6ldHnvckBCe3OjeR?= MV60NOKh|ryP M{jtPFI1KGh? M33RNmROW09? M13IXolv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> MYqyOVczPDh7OR?=
HLCZ01 NGXFU2NCeG:ydH;zbZMhSXO|YYm= NYHiUVZzPDEEoN88US=> MWSyOEBp NWrXUYFXTE2VTx?= NImyTWtmdmijbnPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDJSm4u|rF? MkX0NlU4OjR6OUm=
HLCZ01 M2LBfmZ2dmO2aX;uJGF{e2G7 MYG0NOKh|ryP NIXrT4gzPCCq M1XFNWROW09? NHPp[ZpqdmO{ZXHz[ZMhXFKDSVyg[ZhxemW|c3nvckBkd22kaX7l[EB4cXSqIFnueIVz\mW{b36t{tE> MmrLNlU4OjR6OUm=
MGC803 NITwcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoiwNE03OCEQvF2= M1;VSFczKGh? M2PmV2lEPTB;NEeuNlXjiIoEsfMAjVYvPDNizszN NW\UfpJlOjV5MEGzO|g>
SGC7901 NVvuS5RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm5[ooxNTZyIN88US=> MV63NkBp MkfUTWM2OD12Mz61N-KBkcLz4pEJOU4yOiEQvF2= NHzQ[WQzPTdyMUO3PC=>
MGC803 NXz6SINnTnWwY4Tpc44hSXO|YYm= M3\sblQxyqEQvF2= NILuVZg5NzF4L{K0JIg> NIjsflN2eHKnZ4XsZZR{KEOkbD3iJIV5eHKnc4Ppc44> Ml7yNlU4ODF|N{i=
SGC7901 Mlz1SpVv[3Srb36gRZN{[Xl? MmmzOFDDqM7:TR?= MojGPE8yPi9{NDDo NHrV[mZ2eHKnZ4XsZZR{KEOkbD3iJIV5eHKnc4Ppc44> MXqyOVcxOTN5OB?=
MCF-7  NVHESYJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3uXWY1OS9zMDFOwG0> MVe3NkBp M2nPRWROW09? M1vVN4VvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w MonQNlU3Pjd3MUC=
MDA-MB-231  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq1NU8yOCEQvF2= NEjnU|E4OiCq MUHEUXNQ M1LDS4VvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w NEXUWowzPTZ4N{WxNC=>
MDA-MB-231 Mnj2SpVv[3Srb36gRZN{[Xl? M{DDU|AuPDBiwsXN NUHkZlR3PC1{NDDo M{DPTYlv[3KnYYPld{BEV1hvMjDwdo91\WmwIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> Ml\VNlU2QDd|Mkm=
MCF-7 MVHGeY5kfGmxbjDBd5NigQ>? NUK1Wnh4OC12MDFCuW0> MnfXOE0zPCCq NYjoUGlS\W6qYX7j[ZMhfGinIHXm[oVkfHNib3[gWHBCKG:wIFHCR2czKGW6cILld5Nqd28EoB?= M1e2[FI2PTh5M{K5
MCF7-MX  NVnnUppJTnWwY4Tpc44hSXO|YYm= M3n4[VAuPDBiwsXN NVPPUVFiPC1{NDDo MULlcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW|c3nvcuKh MYWyOVU5PzN{OR?=
MDA-MB-231 MUPGeY5kfGmxbjDBd5NigQ>? MnnPNE01OCEEtV2= NFG1flI1NTJ2IHi= MonEd5RqdXWuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBCSkOJMjD1dEB1dyB2LkK3JJRqdWW|IITvJINwdnS{b3ygcIV3\WxiYomgNVIhcMLi M1\KWVI2PTh5M{K5
A2780 MoP1SpVv[3Srb36gRZN{[Xl? MlG2OU8yOC9zNTFOwG0> MUK0PEBp NEXpcpFl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MV:yOVQzPDh7OB?=
SKOV3  MWXGeY5kfGmxbjDBd5NigQ>? MXu1M|ExNzF3IN88US=> M3qySFQ5KGh? M2nIW4Rm[3KnYYPld{BEd3hvMjDlfJBz\XO|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NX3KTXpQOjV2MkS4PVg>
A2780 NGi3N5FHfW6ldHnvckBCe3OjeR?= NGG3d3Q2NzFyL{G1JO69VQ>? MXG0PEBp M2ntVIVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5? M{[5dFI2PDJ2OEm4
SKOV3  NH3LOVdHfW6ldHnvckBCe3OjeR?= MUO1M|ExNzF3IN88US=> NYXGdGhEPDhiaB?= M4[5[4Vt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5? Mn:wNlU1OjR6OUi=
A2780 NX3jNpIxTnWwY4Tpc44hSXO|YYm= M1O3XVUwOTBxMUWg{txO NVzMR41VPDhiaB?= MmTX[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw NUO5dJRFOjV2MkS4PVg>
SKOV3  MVPGeY5kfGmxbjDBd5NigQ>? NFjmSJE2NzFyL{G1JO69VQ>? MXG0PEBp Mnj2[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw Ml[wNlU1OjR6OUi=
A2780 NULVTG1OTnWwY4Tpc44hSXO|YYm= NXHhS|Z2PS9zMD:xOUDPxE1? M13I[VEhcA>? M3rjZ4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MlvlNlU1OjR6OUi=
SKOV3  NWW4Nlg4TnWwY4Tpc44hSXO|YYm= NHvCTWc2NzFyL{G1JO69VQ>? NGW3S3YyKGh? M4HKZolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYnvTFMyOjV2MkS4PVg>
HCT-15 MYDGeY5kfGmxbjDBd5NigQ>? NEjCWHMyOC13MDFOwG0> M4SwW|YuOzZiaB?= MVzpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ M1vY[VI2OjF6MEK4
HT-29  NGD1W2pHfW6ldHnvckBCe3OjeR?= NV;JToRlOTBvNUCg{txO M2CxUVYuOzZiaB?= MXTpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ MVmyOVIyQDB{OB?=
HSC3  NIfKV3VE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NH7m[WQx6oDVNECg{txO NE\keXg1QCCq NV2yOYxyUUN3ME2yOU42yrFzLke4NEDPxE1? MX:yOVE6QDd6OR?=
HSC3  NW\ifVgzSXCxcITvd4l{KEG|c3H5 MVSyOUDPxE1? MUO0PEBp MnXSbY5lfWOnczDhdI9xfG:|aYO= NWDjOINtOjVzOUi3PFk>
HSC3  NXPrV3FlTnWwY4Tpc44hSXO|YYm= MWiyOUDPxE1? NIjuUoQ1QCCq NF;tV|BmgGirYnn0d{B{cWewaX\pZ4FvfGy7IILl[JVk\WRibXnndoF1cW:wIHPvcYJqdmWmIIfpeIghS0WW MXKyOVE6QDd6OR?=
HSC3  Mn7HSpVv[3Srb36gRZN{[Xl? NIK1eYUzPSEQvF2= MnraOFghcA>? M17NWYlvcGmkaYTzJGhUSzNiY3XscEBqdn[jc3nvckBkd22kaX7l[EB4cXSqIFPFWC=> NWX6NWZbOjVzOUi3PFk>
HSC3  Mmq2SpVv[3Srb36gRZN{[Xl? MU[yOUDPxE1? NYTTU3FRPzJiaB?= NIX4SW5l\WO{ZXHz[ZMhVU2SLUKgZY5lKE2PUD25JJBzd3SnaX7zxsA> M1uzRlI2OTl6N{i5
201T  MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLHWWk4OiCq M{juT2ROW09? M{LCO2lEPTB;NEiuOkDDvU1? NXjTUlBDOjVyNUe5OFE>
273T MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTxSGwxPzJiaB?= NHq5PXRFVVOR MmjuTWM2OD16MD61JOK2VQ>? MXSyOVA2Pzl2MR?=
Hep-2 NXG5[nBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYKzeXVxOzBxNUCvNVAxKM7:TR?= NH;lNlAyOi9{ND:zOk81QCCq MmHKSG1UVw>? NV6xSoxIcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MYiyOFk6QDV4NB?=
Hep-2 NX71U2hUSXCxcITvd4l{KEG|c3H5 MW[1NEDPxE1? M{PnclAuPDhiaB?= MoLOSG1UVw>? M3;wVolv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy MV6yOFk6QDV4NB?=
Hep-2 NUDQWI1pTnWwY4Tpc44hSXO|YYm= MVe1NEDPxE1? M1XkWVAuPDhiaB?= NXzxTlVmTE2VTx?= NWrBW21OemWmdXPld{B1cGVidHXsc41memG|ZTDhZ5Rqfmm2eTDndoFlfWGubIm= M1fMVlI1QTl6NU[0
Hep-2 MknsSpVv[3Srb36gRZN{[Xl? NVPnRZJUPTBizszN MojQNE01QCCq NU\uS4NGTE2VTx?= M1;OWIRm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIHjUSXJV MnHXNlQ6QTh3NkS=
SGC-7901 M4\x[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTkN5gyOC93MD:xNFAh|ryP MlmzNlQwPDhxN{KgbC=> NF[5UHhFVVOR MoPlbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MX[yOFk6Ojl3OB?=
MKN-45 M3\vWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzFWmoyOC93MD:xNFAh|ryP NWHNUG12OjRxNEivO|IhcA>? MoK4SG1UVw>? MlXMbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NGnoPYczPDl7Mkm1PC=>
SGC-7901 MmL1SpVv[3Srb36gRZN{[Xl? MUOxNE82OC9zMECg{txO NU\NbphsPDhiaB?= NETwTHVFVVOR Mlj1[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NIq4WHYzPDl7Mkm1PC=>
MKN-45 M3H6ZWZ2dmO2aX;uJGF{e2G7 MYexNE82OC9zMECg{txO MmG1OFghcA>? MUfEUXNQ NYHCXVJ1\G:5boLl[5Vt[XSnczD0bIUhdVKQQTDlfJBz\XO|aX;uJIxmfmWuczDv[kBEV1hvMjDhcoQhWEOQQTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M3TNZVI1QTl{OUW4
C666-1 MmnZR5l1d3SxeHnjbZR6KEG|c3H5 Mk\INlAuQDBizszN NUDaTFh[OjRiaB?= Mnmy[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> M4DOcVI1QDV2OEO4
CNE-1 NE\YbWJEgXSxdH;4bYNqfHliQYPzZZk> NIXjNoszOC16MDFOwG0> NU\qemZFOjRiaB?= NGrT[4Jl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh M4DYc|I1QDV2OEO4
CNE-2 NH30N|VEgXSxdH;4bYNqfHliQYPzZZk> MUCyNE05OCEQvF2= MXOyOEBp NF36R4xl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh M13ZV|I1QDV2OEO4
C666-1 Mn;IR5l1d3SxeHnjbZR6KEG|c3H5 MUS2NEDPxE1? NFjqTo04KGR? M4HaeYVvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy NX\Ld5dLOjR6NUS4N|g>
CNE-1 M37kcmN6fG:2b4jpZ4l1gSCDc4PhfS=> Ml\lOlAh|ryP M{DMTFch\A>? M37BSoVvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy NIPyUmYzPDh3NEizPC=>
SNU-1041 NV6wRplPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D0OlAuPDBizszN M4rkSFQ5KGh? NE\1fFhqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MkPnNlQ3QTJ5MEO=
SNU-1041 MYjGeY5kfGmxbjDBd5NigQ>? MVyyNE8{OCEQvF2= NICyN5I1KGh? NIfXNJJqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>? M1y2XFI1Pjl{N{Cz
SNU-1041 MkG4SpVv[3Srb36gRZN{[Xl? NUnqeok5OC12MDFOwG0> NY\DNHlVPCCq NIjrcnJ2eC2{ZXf1cIF1\XNiQ1jPVOKh[W[2ZYKgeJJm[XSvZX70JJdqfGhiaHnnbEBkd26lZX70doF1cW:wcx?= M1TtZ|I1Pjl{N{Cz
SGC-7901 MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf3OVAuOTJ3IN88US=> M1HscFI1NzR6L{eyJIg> MkXGbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MXeyOFY4PjN7NB?=
SGC-7901 MlLzRZBweHSxc3nzJGF{e2G7 NHL0WJUyODBizszN M4\WUVczKGh? NWDCOHQ4cW6mdXPld{BieG:ydH;zbZM> M1TKelI1Pjd4M{m0
SGC-7901 NHzJVVNHfW6ldHnvckBCe3OjeR?= MlvTO|UwOTByL{GyOUDPxE1? Mke4NlQwPDhxN{KgbC=> MVvpcoNz\WG|ZYOgZ4F{eGG|ZT24JIFv\CBvOTDtVm5CKGW6cILld5Nqd25iaX6gZo91cCC2aX3lJIFv\CCmb4PlJI1idm6nch?= NULrXZdxOjR4N{[zPVQ>
LMeC  MoX3SpVv[3Srb36gRZN{[Xl? NXG3SopYOjBxNUCg{txO NXfCPWw2PDhiaB?= MoDC[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IIDyc5RmcW5? NVrUb|hmOjR4NU[3OFY>
CMeC-1 MlO1R4VtdCCYaXHibYxqfHliQYPzZZk> MlTDNlAwPTBizszN M4fYT|Q5KGh? MlmxbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M1PNTlI1PjV4N{S2
LMeC MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Moj0NlAwPTBizszN Mom0OFghcA>? NWTsc25lcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M2Ti[|I1PjV4N{S2
CMeC-1 M1nUeWZ2dmO2aX;uJGF{e2G7 M1TVblIxNzVyIN88US=> MV:0PEBp M2LxUolv\HWlZYOgS|EuWyCjcoLld5Q> M3r1TlI1PjV4N{S2
LMeC M3mzXGZ2dmO2aX;uJGF{e2G7 NUPGXXRzOjBxNUCg{txO M{TaTVQ5KGh? M3ewTolv\HWlZYOgS|EuWyCjcoLld5Q> NE\0UXgzPDZ3Nke0Oi=>
CMeC-1 NWi3PIpDTnWwY4Tpc44hSXO|YYm= NFeyV5MzOC93MDFOwG0> M{i5fFQ5KGh? M3r4RYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MkXiNlQ3PTZ5NE[=
LMeC M2fKNmZ2dmO2aX;uJGF{e2G7 Mn\GNlAwPTBizszN NETOTZU1QCCq NH3xb4hl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MkW5NlQ3PTZ5NE[=
CMeC-1 MVLGeY5kfGmxbjDBd5NigQ>? NELYR|czOC93MDFOwG0> NIjaSHU1QCCq NFnmNVhqdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v MUiyOFY2Pjd2Nh?=
LMeC MWTGeY5kfGmxbjDBd5NigQ>? NELRSpczOC93MDFOwG0> MUS0PEBp MoTtbY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> NGf2U3czPDZ3Nke0Oi=>
OVCAR-3 MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWHGSXlDOTBiwsXN NUmzOVFzOSCq NH7Vb|BmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh MnHWNlQ2OjB{Mke=
OVCAR-3 MXnBdI9xfG:|aYOgRZN{[Xl? MnfnNVAhyrWP MoHBNUBp MYDwdo9ud3SnczDwZYNtcXSjeHXsMYlv\HWlZXSgZZBweHSxc3nzxsA> NHLHdYEzPDV{MEKyOy=>
OVCAR-3 M4fWZmZ2dmO2aX;uJGF{e2G7 M17CVFExKML3TR?= M3;iclEhcA>? NEnXRnhmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[WO2aY\heIlwdiCxZjDjZZNx[XOnLUpCpC=> MYKyOFUzODJ{Nx?=
OVCAR-3 Mkf4SpVv[3Srb36gRZN{[Xl? MlHlNVAhyrWP NYnJfG9LOSCq M3KwO4Rwf25vcnXneYxifGW|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=> NH35XG4zPDV{MEKyOy=>
OVCAR-3 MWPGeY5kfGmxbjDBd5NigQ>? Ml\wNVAhyrWP NF[zVFIyKGh? M4Di[YlvcGmkaYTzJJBi[2yrdHH4[YwucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v MWiyOFUzODJ{Nx?=
CF33 NYXnd3R6TnWwY4Tpc44hSXO|YYm= MXGxNFAh|ryP M{HDT|I1KGh? NYXhemg4cW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBEV1hvMjDwdo91\WmwIHX4dJJme3Orb36= NIHz[FgzPDVyM{e4Ni=>
CF33 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKxNE0yODBizszN MViwMVQh\A>? M1v5NolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFzFb3YzPDVyM{e4Ni=>
CF33 NGrBOYJHfW6ldHnvckBCe3OjeR?= NWLpO3hNOTBvMUCwJO69VQ>? NF;nWVA1NTJ2IHi= NH35VYpl\WO{ZXHz[ZMh[2WubIOgbY4hfGinIGOgdIhie2ViYX7kJIlv[3KnYYPld{Bk\WyuczDpckBIOC:JMTDhdpJme3R? NHTsZlYzPDVyM{e4Ni=>
LNCaP MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKyM|UwOTBizszN NWq2O3NHQTZiaB?= NVjkdY9ScW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> NILsNnozPDJ7Nkm3PC=>
LNCaP NHvoVmZCeG:ydH;zbZMhSXO|YYm= M4PEPFIwPS9zMDFOwG0> NHLRWIM6PiCq MlzubY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCjdH;yeoF{fGG2aX6= MVSyOFI6Pjl5OB?=
PC-3  NIHBSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqwMVUxKM7:TR?= MnvKOFjjiImq NIfMc5FqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NWDsSWQ6OjRzMke4PFI>
PC-3  M4DDSWNmdGxiVnnhZoltcXS7IFHzd4F6 NIDqbGsxNTFyMDFOwG0> NECyVnM4OiCq MXvk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MYqyOFEzPzh6Mh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Fibronectin / Vimentin / N-cadherin / E-cadherin ; 

PubMed: 28978083     


(A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells.

COX-2; 

PubMed: 29515134     


L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. 

pAKT / AKT / PPARγ / PTEN ; 

PubMed: 24721996     


Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h. 

28978083 29515134 24721996
Immunofluorescence
PPARγ / PTEN ; 

PubMed: 24721996     


Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.

24721996
Growth inhibition assay
Cell viability; 

PubMed: 28521485     


Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth. 

28521485
In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
- Collapse

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
- Collapse
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635
Smiles CC1=CC=C(C=C1)C2=CC(=N[N]2C3=CC=C(C=C3)[S](N)(=O)=O)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03896113 Recruiting Drug: Celecoxib 200mg capsule Endometrium Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain November 13 2019 Phase 2
NCT03643744 Recruiting Drug: Celecoxib 200mg|Drug: Placebo Actinic Keratosis|Photodynamic Therapy Jeffrey B. Travers MD PhD|Wright State Physicians April 1 2019 Phase 1
NCT01344200 Not yet recruiting Drug: Celecoxib Pharmacokinetics of Celecoxib in Children Children''s Hospital of Eastern Ontario March 2019 Phase 4
NCT02876094 Recruiting Drug: celecoxib Spinal Muscular Atrophy (SMA) Hugh McMillan|Families of Spinal Muscular Atrophy|Gwendolyn Strong Foundation|Children''s Hospital of Eastern Ontario January 29 2019 Phase 2
NCT03672162 Recruiting Procedure: Total abdominal hysterectomy Total Abdominal Hysterectomy Pain Acute PostoperativeGabapentin Celecoxib Rajavithi Hospital September 1 2018 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID